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Outcomes and Safety
of Percutaneous Aortic Valve Replacement
Alan Zajarias, MD,* Alain G. Cribier, MD†
St. Louis, Missouri; and Rouen, France
The concept of transcatheter aortic valve replacement was developed with the goal of offering a therapeutic solution
to patients with severe symptomatic aortic stenosis who are not considered good candidates for surgical valve re-
placement. Initial attempts were complicated by vascular access problems and lack of appropriate tools. With time
and experience, early problems were solved and the concepts of valve sizing, valve positioning, and patient selection
were defined. Technological improvements allowed the use of smaller arterial sheaths to decrease vascular trauma,
special catheters to facilitate valve delivery, and treatments on the valve prostheses that would ensure longer durabil-
ity. After 5 years, the number of transcatheter aortic valve replacements has grown significantly, and will likely con-
tinue as this technology becomes increasingly available. Currently, 2 valve models, the Edwards SAPIEN valve (Ed-
wards Lifescience, Irvine, California) and the CoreValve ReValving system (CoreValve Inc., Irvine, California), have been
used in over 4,000 cases worldwide for the treatment of symptomatic aortic stenosis. Midterm follow-up shows no
evidence of restenosis or prosthetic valve dysfunction. Transfemoral and transapical delivery routes can be selected
depending on the quality of vascular access and the type of prosthesis used. Randomized trials that are currently un-
derway will confirm procedural safety and guide the applicability of this technology. (J Am Coll Cardiol 2009;53:
1829–36) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.11.059v
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ss noted earlier by Ross and Braunwald (1), the natural
istory of symptomatic aortic stenosis (AS) carries a poor
rognosis. Medically treated patients with symptomatic AS
ave a 1- and 5-year survival of 60% and 32%, respectively
2). Aortic valve replacement (AVR) is the only effective
reatment for symptomatic AS that alleviates symptoms and
mproves survival. In the ideal candidate, surgical AVR has
n estimated operative mortality of 4% (3). However, the
ortality rate associated with AVR increases substantially
ith increasing age, the presence of left ventricular dysfunc-
ion, or other comorbidities. These factors are considered
ne of the main reason for which one-third of patients with
alve disease are not referred for surgery (4). Transcatheter
VR opened the possibility of treating patients who until
ow had been left untreated because it was believed that
heir operative mortality outweighed the benefits offered by
raditional AVR.
isk Stratification
he ability to identify high-risk patients is crucial in
ssisting those who would benefit the most from inno-
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Manuscript received May 7, 2008; revised manuscript received November 7, 2008,
ccepted November 13, 2008.ative treatment. Expected operative mortality is calcu-
ated with specific tools that combine clinical, demo-
raphic, and surgical variables that have been shown to
nfluence outcomes. These algorithms were developed to
ompare individual hospital outcomes with population
eans; however, they are also used to provide an esti-
ated risk for patients to facilitate an educated decision
hen considering cardiac surgery. These tools can only
stimate the probability of death of a group of patients with
imilar risk profiles, not the outcome of individual patients (5).
atients are considered to have a high operative risk when their
cores are in the upper decile for mortality or have a 30-day
ortality 15%.
The most commonly used risk calculators are the Society
f Thoracic Surgery Predicted Risk of Mortality (STS-
ROM) and the European System for Cardiac Operative
isk Evaluation (EuroSCORE). The EuroSCORE col-
ects patient variables to generate an estimated operative
ortality rate. Although initially applied to European
atients undergoing coronary artery bypass surgery, it has
een validated in other heterogeneous populations, and
as been applied to valvular surgery as well (6). Because
he prevalence of high-risk patients was low in the initial
opulation that generated this tool, the logistic Euro-
CORE was then developed to more accurately predict
heir mortality (7). However, this algorithm has been
hown to persistently overestimate the mortality rate
5,8). The STS-PROM score is derived from the STS
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practice outcomes, and estimates
the risk of mortality, morbidity,
renal failure, and length of stay
after valvular and nonvalvular car-
diac surgery (9). This score has
been shown to underestimate the
true mortality rate after cardiac
surgery, but it more closely reflects
the operative and 30-day mortality
for the highest-risk patients having
AVR (10).
The STS-PROM and the
EuroSCORE provide an objec-
tive way to quantify risk. Al-
though thorough, these risk
scores do not include certain
haracteristics that would complicate surgery and increase
he operative mortality, such as: previous mediastinal
rradiation, the presence of a severe calcification in the
horacic aorta (porcelain aorta), anatomical abnormality
f the chest wall, history of mediastinitis, cirrhosis, or
atient’s frailty. In addition, the algorithms were calcu-
ated from patients who underwent surgery, thus limiting
heir applicability to patients who were not considered
urgical candidates. Clinical judgment and the patient’s
evel of independent function are subjective parameters
hat influence outcomes after cardiac surgery but are
ifficult to measure. In clinical trials, risk calculators can
bjectively standardize patients; however, these tools
hould be used in conjunction with clinical judgment to
ppropriately select patients who will benefit the most
rom therapeutic interventions.
Abbreviations
and Acronyms
AI  aortic insufficiency
AS  aortic stenosis
AVR  aortic valve
replacement
BAV  balloon aortic
valvuloplasty
EOA  effective orifice
area
LVEF  left ventricular
ejection fraction
MACCE  major adverse
cardiovascular and
cerebrovascular events
Figure 1 Profile of the Edwards SAPIEN Transcatheter Heart Va
The Edwards SAPIEN transcatheter aortic prosthesis is mounted on a balloon-expa
bovine pericardial prosthesis is attached to the stent and treated with an anticalci
decreases perivalvular leaks.ercutaneous Aortic Valve Prostheses
ranscatheter AVR has evolved significantly since its cre-
tion. Six years after the report of the first successful valvular
mplantation (11), multiple valve prototypes have been
eported and are currently in different stages of develop-
ent. The Edwards SAPIEN valve (Edwards Lifescience,
rvine, California) and the CoreValve ReValving system
CoreValve Inc., Irvine, California) contribute the largest
atient experience and are the focus of the remainder of this
aper.
dwards SAPIEN Valve
he Edwards SAPIEN valve is a bovine pericardium
rosthesis mounted on a balloon-expandable stent that is
laced in the subcoronary position. It can be placed by an
ntegrade, retrograde, or transapical approaches (Fig. 1).
ntegrade Approach
he initial report of a successful percutaneous implantation
f an aortic bioprosthesis in a patient with severe symptom-
tic AS who presented in cardiogenic shock in April 2002
as greeted with enthusiasm (11). From 2003 to 2004,
ingle-center registries to document the feasibility of the
rocedure, on a compassionate basis, were started under the
ames of I-REVIVE (Initial Registry of Endovascular
mplantation of Valves in Europe) and RECAST (Registry
f Endovascular Critical Aortic Stenosis Treatment) (12).
hese registries used a 23-mm bioprosthesis made of equine
ericardium mounted on a stainless steel balloon-expandable
tent. Valve placement was primarily done via the antegrade
transseptal) approach. Procedural success was achieved in
stainless steel stent that is placed in the subcoronary position. The trileaflet
n treatment. The stent has a polyethylene terephthalate fabric skirt thatlve
ndable
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May 19, 2009:1829–36 Outcomes of Percutaneous AVR5%. Aortic valve area increased consistently from 0.6 to 1.6
m2 and was accompanied by a decrease in mean transval-
ular gradient (37 to 9 mm Hg) and an increase in left
entricular ejection fraction (LVEF) (45% to 53%). The
0-day mortality rate was 23% and the 30-day major adverse
ardiovascular and cerebrovascular events (MACCE) rate
as 26% (13). Patient survival was 63% by 6 months, and
as limited by the severity of patient comorbidities.
Moderate to severe perivalvular aortic insufficiency (AI),
een in 63%, and valve embolization were procedural limi-
ations caused by the availability of a single valve size (23
m in diameter). Because of venous distensibility, sheath
nsertion was not limited by vessel size, tortuosity, or the
resence of peripheral vascular disease. Valve placement was
imple because the device crossed the smooth aspect of the
ortic valve. However, the technique was challenging be-
ause of the need for a transseptal puncture, the navigation
f the catheter/valve ensemble across the mitral and aortic
alve, and the guidewire interaction with the mitral valve
nd subvalvular apparatus, contributing to poorly tolerated
cute mitral insufficiency. The summation of all of these
roblems limited the diffusion of this approach, prompted
echnical improvements in the delivery system, and pro-
oted the resurgence of the retrograde approach.
etrograde Approach
ignificant technical and prosthetic modifications followed
o solve the previously encountered limitations. To reduce
he degree of perivalvular regurgitation, valves were over-
ized in relation to the aortic annulus, and a second
rosthesis size, 26 mm, became available. The transverse
iameter of the aortic annulus at the level of aortic leaflet
nsertion was identified for appropriate valve sizing. In
ddition, the necessary landmarks for valve positioning were
ecognized, decreasing the risk of valve embolization. A
atheter with a manually activated deflectable tip (Retroflex
atheter, Edwards Lifescience), which aids in the atraumatic
assage across the aortic arch and in centering the guidewire
hrough the aortic commissures, facilitated the valve deliv-
ry through the retrograde approach. Modifications in the
elivery sheath also reduced vascular complications. Sheath
ength was increased to deliver the catheter/valve ensemble
irectly in the descending aorta, decreasing the risk of
ascular injury (14). Minimal arterial diameter, vessel tor-
uosity, and vessel calcification were still the major limiting
actors.
Multicenter registries from the U.S. (REVIVAL II [tRans-
atheter EndoVascular Implantation of VALves II] trial),
uropean Union (REVIVE II [Registry of EndoVascular
mplantation of Valves in Europe II]), and Canada (Canadian
pecial Access) included patients with a valve area 0.8 cm2
nd a high predicted operative mortality (logistic EuroSCORE
20%) to continue to evaluate procedural safety and efficacy.
ew valve modifications were added to improve long-termunction, which included: use of bovine pericardium, elonga-
i
Aion of the skirt to decrease perivalvular insufficiency, and the
ddition of an anticalcification treatment, culminating in the
rosthesis that is currently used. The series of retrograde
mplantation published by Webb et al. (14) showed initial
rocedural success of 78%, which increased to 96% after the
rst 25 cases, reflecting an important learning curve (15). The
bserved 30-day mortality was 12%, whereas the expected
0-day mortality was 28%. At median follow-up, there was no
vidence of valve deterioration, migration, or valvular insuffi-
iency. Moderate perivalvular leaks were seen in 3 cases at 1
onth. Perivalvular AI was mild, clinically inconsequential,
nd stable during follow-up in the majority of the patients
Table 1).
Reported data of patients with severe AS who underwent
ranscatheter AVR in the European Union (Edwards Sa-
ien Aortic Bioprothesis European Outcome Registry [n 
98], T. Lefevre, personal communication, October 2008)
how a 95% implant success (16). The improvement in
ffective orifice area (EOA), LVEF, and mean aortic gradient
choed the previously reported results. In addition, 65% had
I 1/4, and 26% had grade 2/4 at 6 months. Of the 79.2%
f patients with New York Heart Association functional class
II to IV symptoms, only 10% persisted with this degree of
imitation at 30 days after implantation. The 30-day survival
ymptoms, Outcomes, and Adverse Events Afteretrograde Transcatheter Aortic Valve Replacementsing the Edwards SAPIEN Valve
Table 1
Symptoms, Outcomes, and Adverse Events After
Retrograde Transcatheter Aortic Valve Replacement
Using the Edwards SAPIEN Valve
Frequency
Webb et al. (15)
(N  50)
SOURCE Registry (16)
(N  305)
Age, yrs 82 7 81.8
NYHA functional class III/IV
(before), %
90 79.2
NYHA functional class III/IV
(3 months), %
3 10
Logistic EuroSCORE, % 28 26.4
AVA (before), cm2 0.6 0.59
AVA (after), cm2 1.7 1.7
Mean gradient (before), mm Hg 46 17 53.5
Mean gradient (after), mm Hg 11 5 3.95
LV ejection fraction (before), % 53 15 NA
LV ejection fraction (7 days), % 57 13 NA
Procedural success, % 86 95
Adverse events, %
Procedural mortality 2 0.3
30-day mortality 12 6.4
CVA 4 3.4
MI 2 1
Tamponade 2 0.7
Vascular compications NA 7.4
Transfusion 3 U 18 NA
Heart block 4 NA
Surgery 0 NA
AI 3 13 NA
I  aortic insufficiency; AVA  aortic valve area; CVA  cerebrovascular accident; EuroSCORE 
uropean System for Cardiac Operative Risk Evaluation; LV  left ventricular; MI  myocardial
nfarction; NA  not available; NYHA  New York Heart Association; SOURCE  Edwards Sapien
ortic Bioprothesis European Outcome Registry.
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Outcomes of Percutaneous AVR May 19, 2009:1829–36as 93.6%. Transcatheter AVR was aborted in 2.3% primarily
ecause of failed arterial access and inability to cross the valve.
ntraprocedural death was 0.3%, 30-day mortality was 6.4%,
erebrovascular events occurred in 3.4%, and vascular compli-
ations occurred in 7.4%, as detailed in Table 1. The presence
f vascular complications increase mortality considerably, sug-
esting careful patient selection.
In September 2007, the Edwards SAPIEN valve, as it is
ow known, achieved the CE mark in the European
ommunity, prompting diffusion of the technology and use
f out of research protocol for high-risk individuals. Pre-
iminary results from an ongoing registry note maintenance
f the safety profile with the diffusion of the technology to
enters outside those involved in clinical trials. A multi-
enter randomized trial, PARTNER US (Placement of
oRTic traNscathetER), whose primary end point is 1-year
ortality, is currently enrolling patients in the U.S. and
anada. The trial includes patients with severe symptomatic
S who are poor surgical candidates, and has 2 treatment
rms. An arm powered for superiority analysis compares
ptimal medical treatment and balloon aortic valvuloplasty
BAV) to transcatheter AVR in patients who are deemed
noperable, whereas a noninferiority analysis will be applied
o the arm that compares traditional AVR with transcath-
ter AVR in patients with elevated surgical risk (STS score
10%). Results for this trial will determine the diffusion of
ranscatheter AVR, and will help establish conditions for
uture use.
ransapical Approach
he transapical approach is the most recently developed
orm of transcatheter AVR. Initial experience in an animal
odel has been able to be extrapolated to early human
xperience with promising results (17–19). The procedure
nvolves a small left lateral thoracotomy and should be
erformed in a hybrid operative suite. It requires a direct
uncture and sheath insertion into the left ventricle. A
uidewire is used to cross the aortic valve, and the rest of the
rocedure follows the same steps involved in valve prepara-
ion and deployment as described for the retrograde ap-
roach. The introduction of the valve catheter requires the
scendra Transapical Delivery System (Edwards Life-
cience).
The first published data from Lichtenstein et al. (18)
onsisted of 7 high-risk patients with AS. Valve implanta-
ion was successful in all of them, and there were no
rocedural deaths. Transvalvular gradient and aortic valve
rea improvement was seen in all patients, and the results
ere consistent with those found after retrograde implan-
ation. Observed 30-day mortality was lower than the
xpected mortality (14% vs. 35%) (17,18). Published mul-
icenter experience using this innovative approach is limited.
alther et al. (20) reported on 93.2% successful implanta-
ions with a conversion rate to traditional AVR of 6.8%.
hese high-risk patients had a median intensive care unit ptay of 20 h. Trace to mild AI was seen in 23 patients. The
0-day mortality was 13.6%, whereas the predicted opera-
ive mortality was 26.8%. Use of extracorporeal circulatory
upport was frequent (47%) during the initial procedures;
owever, after familiarization of the technique, the use
ecreased. Currently, prophylactic insertion of venous
uidewires is done in all cases, but use of extracorporeal
irculation is rare. A recently published U.S.-based feasibil-
ty study noted successful valve placement in 90% of the
ases accompanied by persistent improvement in symptoms,
alve area, mean gradient, AI, and quality of life (21).
orty-seven percent of the patients were considered inop-
rable, and their mean STS score was 13.4%. Patient
urvival was 81.8% at 1 month, 71.7% at 3 months, and
8.7% at 6 months. In 65%, MACCE were seen and
ncluded a 5% incidence of stroke, 2.5% need for emergent
ardiac surgery, and 17.5% myocardial infarction rate.
Interim analysis of data from a large series (n  168) of
igh-risk patients treated with the transapical AVR in-
luded in the TRAVERCE (Trans-Apical surgical Delivery
f the Cribier-Edwards Aortic Bioprothesis Clinical Feasi-
ility) study are shown in Table 2 (22). Correct placement
as seen in 92.8% of the cases, and only 7.1% had to be
onverted to open AVR. Improvement in LVEF and aortic
alve area was seen, whereas appropriate valve function was
aintained during follow-up. The overall 6-month survival
as 70% for this technique. Cerebrovascular events, ar-
hythmias, and partial coronary occlusion were seen in 2.9%,
.4%, and 1.8%, respectively. Ventricular bleeding at the
uncture site was seen in 4.8%. Aortic insufficiency, valve
alposition, and valve migration were the most common
auses contributing to an unsuccessful procedure followed
y perivalvular AI. Placement of a second valve (valve-in-
alve) was required in 3% to decrease the AI or correct valve
alposition.
The differences in outcomes of the previously reported
eries reflect the complexity of the technique and the
mportance of appropriate patient selection. Patients who
equire the transapical approach have a higher incidence of
eripheral vascular disease, which is a marker of worse
ong-term outcome. Although smaller, the U.S. feasibility
eries consisted of a sicker patient population with a higher
stimated mortality. The U.S. transapical programs were
emporarily interrupted, causing the need to re-learn the
rocedure, which may have contributed to the morbidity.
lthough in its early stage, transapical AVR has the potential
f becoming a new option for the treatment of high-risk
atients requiring AVR. Patients who require AVR but have a
porcelain aorta” or have peripheral vascular disease that limits
heir candidacy for retrograde transcatheter AVR should be
onsidered for the transapical approach.
oreValve ReValving System
he CoreValve ReValving system is a percutaneously placed
orcine pericardial bioprosthesis designed for the aortic
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May 19, 2009:1829–36 Outcomes of Percutaneous AVRosition. It is mounted in a self-expanding nitinol frame
hat extends from the left ventricular outflow tract into the
ortic root. The frame has 3 dedicated functional areas that
llow proper orientation, anchoring, and valve placement.
he valve rests in a constrained supra-annular position
voiding interference with the coronary ostia and is used
o treat AS. The prosthesis is sized according to the left
entricular outflow tract diameter. The CoreValve
eValving system has the advantage being self-centering
nd partially repositionable, allowing for more liberty
uring deployment (Fig. 2).
Patients included in the published registries were char-
cterized by having: 1) severe AS; 2) aortic annular dimen-
ions between 20 and 27 mm and an ascending aortic
iameter of 45 mm; and 3) age 80 years with a
uroSCORE 20%, age 75 years and EuroSCORE
15%, or age 65 years and 1 of the following: cirrhosis,
espiratory failure, pulmonary hypertension, previous car-
iac surgery, right ventricular failure, chest radiation, or a
urned chest that would complicate AVR.
Initial designs used a 24-F system that required full
nesthesia, extracorporeal circulation, and a surgical cut-
own for device placement. New-generation devices quickly
ollowed that decreased the delivery sheath size to 21- and
8-F subsequently, converting the procedure to a com-
letely percutaneous one. Published data from the original
ohort that used the 24- and 21-F systems described 25
atients with high risk for AVR. Patients were predomi-
antly women (80%) with a mean age of 80 years and had
ymptoms, Outcomes, and Adverse Events After Transapicalranscatheter Aortic Valve Replac ment Using the Edwards SAPIE
Table 2 Symptoms, Outcomes, and Adverse Events After TransTranscatheter Aortic Valve Replacement Using the Edw
Walther et al. (20) (n  59)
Age, yrs 81.4 5.8
NYHA functional class (before) 3.4 0.5
NYHA functional class III/IV (after) NA
AVA (before), cm2 0.5 0.15
AVA (after), cm2 NA
Mean gradient (before), mm Hg NA
Mean gradient (after), mm Hg 9 6
LV ejection fraction (before), % 47 16
LV ejection fraction (after), % NA
Procedural success, % 93.2
Logistic EuroSCORE, % 26.8 13.5
6-month survival 75.7
Adverse events
30-day mortality 13.6
30-day stroke 3
Conversion to open AVR 6.8
MI NA
Bleeding 7
Pacemaker NA
Severe AI 2
VR  aortic valve replacement; other abbreviations as in Table 1.ultiple comorbidities. The acute device success, defined assuccessfully placed valve, was 88%. Procedural success,
efined as device success and absence of MACCE at 48 h,
as 68%. The mean aortic valve gradient decreased from
4.24 10.79 mm Hg to 12.38 3.03 mm Hg acutely and
as unchanged at 30 days (23). Post-procedure AI de-
reased or was unchanged in 78%. Severe AI was not seen in
atients with a successfully deployed valve. Two patients
ad immediate conversion to open AVR because of valve
ve
l
SAPIEN Valve
Frequency
Svensson et al. (21) (n  40) Walther (22) (n  168)
83 7.5 82 6
3.33 3.23 0.4
NA 16%
0.62 0.12 0.6 0.2
1.61 0.37 1.5
40.2 9.8 43.1 16.5
7.7 2.5 8
51.5 15.1 53 6
55 19.2 52.9
90 92.8
35.5 15.3 27 13
58.7 70
17.5 15
5 2.9
2.5 7.1
17 1.2
NA 4.8
NA 5.9
0 0
Figure 2 Profile of the CoreValve ReValving System
The CoreValve transcatheter aortic heart valve is a self-expanding nitinol frame
porcine pericardium prosthesis developed for the treatment of aortic stenosis,
regurgitation, and failing surgical bioprosthesis. The frame has 3 distinct func-
tional levels with different radial and hoop strengths. The valve is placed
across the left ventricular outflow tract and extends into the aortic root.N Val
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Outcomes of Percutaneous AVR May 19, 2009:1829–36alposition, and BAV was the only treatment given to
nother when the prosthesis was unable to cross the native
asculature. In-hospital MACCE events were seen in 32%
nd included a 20% mortality rate and major bleeding in
4%. Thrombocytopenia was seen in all patients with
irculatory support.
The use of extracorporeal circulatory support quickly
eclined as smaller-diameter catheters became available, and
onsequentially so did the presence of thrombocytopenia
nd bleeding. With completion of the learning curve, the
ACCE rate decreased as well. A comprehensive series
n  86) using the 21- and 18-F devices included high-risk
atients with similar clinical characteristics. The acute
evice success rate was 88%, and the procedural success at
8 h was 74% (24). Two patients required a second
rosthesis to reduce the degree of AI. The aortic valve area
ncreased acutely, post-procedural AI improved or remained
nchanged in 66%, and severe AI was not seen after
uccessful device deployment (24,25). With the use of the
8-F delivery system, procedural duration diminished, cir-
ulatory support was no longer used, and the procedure
ecame truly percutaneous without the need of a surgical
ut-down (Table 3). The CoreValve ReValving system
chieved the CE mark in 2007, and since then a multicenter
egistry using the 18-F prosthesis has been created. Recently
ublished results show a procedural success rate of 97% with
.5% procedural mortality (26,27). Hemodynamic improve-
ent continues with a significant decrease in the mean
ortic gradient and an increase in the aortic valve area.
ymptoms, Outcomes, and Adverse Events After Retrograderanscatheter Aortic Valve Replac ment Using the CoreValve ReVa
Table 3 Symptoms, Outcomes, and Adverse Events After RetroTranscatheter Aortic Valve Replacement Using the Co
Grube et al. (24)
(21-F  18-F) (n  86)
Age, yrs 82 5
NYHA functional class III/IV (before), % 83
NYHA functional class mean (after) 1.85
AVA (before), cm2 0.6
AVA (after), cm2 NA
LV ejection fraction (before), % 54
Mean gradient (before), mm Hg 43.7 15
Mean gradient, mm Hg 9
Procedural success, % 74
Logistic EuroSCORE, % 23.4
Adverse events, %
Procedural mortality 6
30-day
Mortality 12
Stroke/TIA 10
MI 1
Tamponade 7
Coronary obstruction 0
Aortic dissection 0
AI 3 0
Pacemaker NAIA  transient ischemic attack; other abbreviations as in Table 1.evere perivalvular AI, procedural stroke, and tamponade
ave become negligible. Permanent pacemaker implantation
as required in 9.3% and seems to be a function of
rosthesis position (Table 3) (26).
ther Aortic Prosthesis
econd-generation transcatheter aortic valve prototypes,
uch as the Lotus (28) (Sadra Medical, Saratoga, Califor-
ia), AorTx (Hansen Medical, Mountain View, California),
irect Flow (Direct Flow Medical, Inc., Santa Rosa,
alifornia) (29), and Paniagua PHV (Endoluminal Tech-
ology Research, Miami, Florida) among others, are under-
oing first-in-man implantations. Design innovations that
llow the use of smaller arteriotomies and the freedom to
eposition the prosthesis and decrease the rate of perivalvu-
ar insufficiency create attractive options for the future.
heir availability will depend on the result of initial feasi-
ility registries and how they perform against the older-
eneration devices.
atient Selection
atient selection is crucial for transcatheter AVR success.
andidates considered for transcatheter AVR must have
evere symptomatic AS in addition to a formal contrain-
ication to surgery or other characteristics that would
imit their surgical candidacy because of excessive mor-
ality or morbidity risk. The procedure should be offered
o patients who have a potential for functional improve-
System
ve ReValving System
Frequency
Piazza et al. (26)
(18-F Registry) (n  112)
Laborde et al. (27)
(18-F Expanded Registry) (n  1,243)
81 6.6 81 6.4
85 84
NA NA
0.6 0.2 0.64 0.19
NA 1.5
51.5 13.9 52.1 14
49.4 13.9 49.6 16.8
3.2 5.2 9.1
97 98
23.5 13.9 22.9 4.1
1.5 1.7
8 6.7
0.6 1.7
0.5 3.9
1.4 2.3
0 NA
0.6 0.4
0 0.8
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May 19, 2009:1829–36 Outcomes of Percutaneous AVRent after valve replacement. Anatomical criteria must
e met to facilitate valve delivery and placement. Tortu-
sity, calcification, and minimal luminal diameter of the
orta, iliac, and femoral arteries influence patient selec-
ion and the implantation route. Patients with heavily
alcified, small, tortuous arteries should undergo place-
ent through a transapical approach to prevent vascular
omplications. The transfemoral approach should be
tilized in patients with iliofemoral arteries that meet the
ecessary characteristics. The minimal vessel diameter
equired for sheath insertion in the transfemoral ap-
roach is 7 and 8 mm for the 22- and 24-F catheters,
espectively, for the Edwards SAPIEN valve. Smaller
rterial diameters (6 mm) are accepted with the Cor-
Valve ReValving system because its delivery catheter is
8-F. The presence of basal left ventricular septal hyper-
rophy may interfere with valve delivery and predispose to
alve migration.
The transcatheter heart valve must be slightly larger than
he aortic annulus to decrease the amount of perivalvular AI
nd achieve appropriate valve anchoring. Currently, only
atients with an aortic annulus diameter of 18 to 24 mm can
e considered for placement of an Edwards SAPIEN
rosthesis; a 23-mm valve is used when the annulus diam-
ter is between 18 and 21 mm, whereas a 26-mm prosthesis
s sized for an annulus of 21 to 24 mm. The CoreValve
eValving system uses a 26-mm valve for an annulus
iameter of 20 to 23 mm and a 29-mm valve for a 23- to
7-mm annulus. A larger aortic annulus may provide
nappropriate support for the stent frame and may be
ssociated with valve embolization. Marked oversizing of
he prosthesis may cause aortic annular rupture in patients
ith a calcified aortic root.
Patients with bicuspid aortic valves are not optimal candi-
ates for transcatheter heart valve implantation because the
alvular orifice is elliptical and may predispose to perivalvular
I (30). Future valve prostheses may overcome this limitation.
he presence of concomitant AI is not a contraindication to
ranscatheter valve replacement as long as the predominant
esion is AS, the mechanism of AI is not annular dilation, and
he required annular dimensions for valve seating exist. Patients
ith low-gradient AS and poor ventricular function can be
onsidered for transcatheter heart valve implantation; however,
t is unclear whether this therapy may alter their prognosis. The
ompletion of the PARTNER US trial may elucidate the role
f transcatheter AVR in these patient subsets. The experience
f transcatheter aortic prosthesis in noncalcific degenerative AS
rheumatic) is limited and currently cannot be recommended.
AV
he use of BAV for the treatment of degenerative, calcific
S was introduced in 1986 (31). It acutely increases aortic
alve area and decreases patients’ symptoms; however, it is
ccompanied by a 80% restenosis rate at 1 year (32). After
ts introduction, the use of BAV declined because of thelevated mortality and complication rate (33). The use of
alloons that require a smaller arteriotomy size, pre-shaped
uidewires, and rapid ventricular pacing has been associated
ith a lower mortality (4%) and complication rate (6%)
34). Current American College of Cardiology/American
eart Association Guidelines only recommend the use of
AV as a bridge to surgery in hemodynamically unstable
atients with severe AS who are at high risk for AVR, or as
reasonable treatment for symptom palliation in patients
ith severe AS who cannot undergo AVR because of serious
omorbid conditions (35). Familiarity with the BAV tech-
ique is necessary for transcatheter AVR because it is part of
he implantation procedure. A BAV may be used for
ymptom palliation in patients awaiting transcatheter AVR,
or accurate prosthesis sizing, and to predict possible coro-
ary occlusion in patients with nodular calcifications in the
ortic valve leaflets.
onclusions
ranscatheter AVR holds the potential of offering lifesaving
reatment to patients with severe AS who are currently
ndertreated. The ongoing PARTNER US trial will at-
empt to identify the role of transcatheter AVR in patients
ith severe symptomatic AS who have a high surgical
ortality risk. Physicians must evaluate patients’ needs and
xpectations knowing that in certain situations, comfort,
ymptom relief, and avoidance of morbidity are more
mportant than increased longevity. Today, transcatheter
VR should remain limited to high-risk patients, and
ncontrolled diffusion should be avoided. In the future, if
he results continue to be favorable, increased indications for
his technology may become available.
eprint requests and correspondence: Dr. Alain G. Cribier,
ervice de Cardiologie, Hôpital Charles Nicolle, 1 Rue de Ger-
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